Drug intelligence / Profile preview

atg-112

Development stage: Preclinical
Lead developer: Antengene
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ATG-112 is a bispecific T-cell engager (BiTE) targeting ALPPL2 (alkaline phosphatase, placental-like 2) and CD3. It is being developed as a potential therapy for solid tumors. The drug is designed to bind both tumor cells expressing ALPPL2 and T cells expressing CD3, thereby redirecting T-cell cytotoxicity towards the tumor. The mechanism involves inhibiting ALPPL2 (possibly affecting the tumor microenvironment or tumor cell growth) and stimulating CD3 (activating T cells for tumor destruction)[7]. As of May 2025, ATG-112 is in the preclinical stage of development[7].

Targets

ALPG (Alkaline phosphatase, placental-like 2)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on atg-112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atg-112.

Explore the full profile